Apogee Therapeutics (APGE) Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary

Strategic focus and differentiation

• Developing best-in-class antibodies targeting large markets, with a lead program in atopic dermatitis showing rapid itch relief and improved dosing potential.

• Pipeline aims for three to six-month dosing, optimized efficacy, and single 2 mL injections across multiple indications including asthma, EOE, and COPD.

• Competitive advantage built on early innovation, accelerated clinical progress, and a strong IP and combination therapy strategy.

• Over $900 million in funding supports aggressive development and market entry ahead of biosimilar competition.

• Focus on combination co-formulations rather than bispecifics to optimize dosing flexibility and efficacy.

Market landscape and commercial outlook

• Recent launches in the atopic dermatitis biologic market (NEMLUVIO, EBGLYSS) are annualizing at $500–$650 million, with market growth over 25% year-over-year.

• Biologic penetration in atopic dermatitis remains low at 10%, compared to 25–30% in psoriasis and 60% in IBD, indicating significant growth potential.

• Payers are granting rapid first-line access to new entrants, with coverage rates of 80–90% for recent launches.

• High physician and patient preference is expected to drive prescription volume and payer access for new therapies.

Clinical development and data highlights

• Phase IIa data for APG 777 in atopic dermatitis showed lesion improvements comparable or superior to DUPIXENT and rapid itch relief similar to NEMLUVIO.

• Two-thirds of patients achieved EASI 75, outperforming DUPIXENT and LEBRI benchmarks.

• Maintenance and induction data from ongoing studies will inform phase III dosing regimens, with both three- and six-month dosing being pursued.

• Early data show a 15% reduction in itch within 48 hours, matching or exceeding competitors.

• Phase III trials are planned to start in the second half of 2026, with key maintenance data expected in Q1 2026.